Literature DB >> 6401187

The characteristics of a monoclonal antibody that binds specifically to rat T lymphoblasts and inhibits IL 2 receptor functions.

H Osawa, T Diamantstein.   

Abstract

In order to obtain an anti-interleukin 2 (IL 2) receptor antibody, we immunized mice with phorbol myristate acetate-pulsed rat T lymphoblasts. The spleen cells of the mice were fused with myeloma cells. Several stable clones of hybridoma cells were obtained that produced monoclonal antibodies (mAb) reacting specifically with rat T lymphoblasts. Only one of these mAb, the mAb ART18, showed characteristics of a putative anti-IL 2 receptor antibody. This mAb was produced on a large scale, purified, and characterized. As tested by a binding assay, 125I-labeled mAb ART18 bound to rat T lymphoblasts (7.5 X 10(4) binding sites per cell), but not to thymocytes or spleen cells of rat origin, or to lymphoblasts, thymocytes, or spleen cells of murine origin. Only marginal binding to lipopolysaccharide-stimulated rat lymphoblasts was detected. The mAb ART18 inhibited in a species-specific and dose-dependent manner i) the capacity of rat T lymphoblasts to absorb IL 2 activity and ii) the capacity of rat T lymphoblasts to proliferate in response in IL 2. The function of T lymphoblasts of murine origin was not affected by the mAb ART18. The time course of the acquisition by mitogen-stimulated spleen cells of the capacity to absorb IL 2 activity was paralleled by that of their capacity to bind 125I-labeled mAb ART18. According to these data, the mAb ART18 seems to be directed against an antigenic determinant of the IL 2 receptor molecule.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401187

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  Gamma interferon treatment in vivo provokes accumulation of activated monocytes in the venous circulation of rats.

Authors:  B Steiniger; D Schröder; R Lück; L Luciano; P H van der Meide
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

2.  Generation of cytotoxic T cells in the rat mixed lymphocyte reaction is blocked by monoclonal antibody MRC OX-8.

Authors:  J R Green
Journal:  Immunology       Date:  1984-06       Impact factor: 7.397

3.  Immunohistochemical localization of cells reacting with monoclonal antibodies directed against the interleukin-2 receptor of murine, rat and human origin.

Authors:  L Takacs; H Osawa; I Törö; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

4.  Pretreatment with cyclosporine and anti-interleukin 2 receptor antibody abrogates the anti-idiotype response in rat recipients of cardiac allografts.

Authors:  K Tanaka; N L Tilney; K G Stunkel; W W Hancock; T Diamantstein; J W Kupiec-Weglinski
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  IL-2 receptors on rabbit T-cell lines and their transfectants expressing the human IL-2 receptor alpha chain.

Authors:  Y Yamamura; M Kotani; M Tsudo; H Karasuyama; A Seto; M Miyasaka
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

6.  Expression of MHC class II antigens on bile duct epithelium in experimental graft versus host disease.

Authors:  L Takács; B Szende; A Rot; T Diamanstein
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

Review 7.  Regulation of lymphocyte growth by antagonists of interleukin-2 or its cellular receptor.

Authors:  G N Gaulton; J F Markmann
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

8.  Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

Authors:  J W Kupiec-Weglinski; T Diamantstein; N L Tilney; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

9.  Anti-IL-2 receptor monoclonal antibody AMT-13 increases soluble IL-2 receptor levels in vivo.

Authors:  K Burkhardt; T E Mandel; T Diamantstein; M S Loughnan
Journal:  Immunology       Date:  1989-02       Impact factor: 7.397

10.  Suppression of pulmonary injury in experimental 'Goodpasture's syndrome' by deoxyspergualin (DSP).

Authors:  H Y Lan; D J Nikolic-Paterson; M Zarama; P G Kerr; R C Atkins
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.